A written quote tells you what the price covers

PRP for a shoulder is commonly paid in cash

PRP is the short name for platelet-rich plasma. Clinic staff draw blood and use a machine to separate it. They save the portion rich in platelets, which are tiny blood parts that help seal a wound and begin repair. That blood portion is prepared for the shoulder procedure during the visit.

Medicare's national rule doesn't cover PRP for shoulder soreness. It covers PRP only for certain wounds that won't heal. Private health plans set their own terms. Ask the clinic for the billing code, then call your plan. Have the plan send its answer in writing before you pay.

Coverage tells you who pays, not whether you will feel better.

A useful quote names the care and the follow-up

Ask exactly what will be placed in the shoulder and who performs the procedure. Find out whether that person often performs shoulder procedures. Check whether a scan is used to guide placement. The quote should also name later visits, limits on arm use, and help you may need at home. Ask what happens if the soreness doesn't ease.

Before calling, list the movements you want back and the medicines you take. Bring your insurance answer as well. Those notes keep the visit focused on your shoulder, your daily needs, and your budget.

At QC Kinetix in Chandler, staff can explain the price and follow-up for regenerative treatments, which are options that don't use surgery.

Sources

1. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446), and centres claimed a mean clinical efficacy of 82% (SD 9.6%) - a figure with no support in the published evidence. The gap between the quoted number and the trial data is the single most useful thing a patient can be told before a consultation.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. The journal of knee surgery, 2018. DOI: 10.1055/s-0037-1604443.

2. Medicare's National Coverage Determination covers autologous platelet-rich plasma ONLY for chronic non-healing diabetic, pressure or venous WOUNDS, and only under Coverage with Evidence Development inside an approved clinical research study. There is no Medicare coverage pathway for PRP as a treatment for osteoarthritis or any other joint indication, which is why these injections are quoted as cash prices.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2012.

3. In January 2025 the Federal Trade Commission banned the co-founders of a stem cell institute and their companies from marketing stem cell treatments and ordered them to pay more than $5.1 million in refunds and civil penalties. Deceptive EFFICACY ADVERTISING, not merely unapproved manufacturing, is independently actionable - the FTC polices what a clinic promises as well as what it injects.

   US Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. FTC Press Release, 2025.

4. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development study. There is no Medicare national coverage for PRP in shoulder osteoarthritis or rotator cuff disease, which is why these injections are billed to the patient directly.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

5. A meta-analysis with a formal cost-effectiveness analysis found PRP did not reduce retear risk across all tear sizes (RR 0.87, 95% CI 0.67-1.12) but did for small and medium tears under 3 cm (RR 0.60, 0.37-0.97; number needed to treat 14). At an incremental cost-effectiveness ratio of US$127,893 per quality-adjusted life year, the authors concluded PRP was NOT cost-effective even where it worked.

   Vavken P, et al. — Platelet-Rich Plasma Reduces Retear Rates After Arthroscopic Repair of Small- and Medium-Sized Rotator Cuff Tears but Is Not Cost-Effective.. Am J Sports Med, 2015. DOI: 10.1177/0363546515572777.

6. A 2026 meta-analysis of 21 studies (1,279 patients) found leukocyte-poor PRP augmentation at rotator cuff repair reduced structural retear risk (overall RR 0.74, 95% CI 0.55-0.99), with the benefit clearest in medium-sized tears (RR 0.68). Patient-reported outcomes did NOT improve consistently, publication-bias diagnostics indicated small-study effects (Egger p=0.017), and trim-and-fill adjustment moved the estimate to a non-significant RR 0.91 (0.69-1.19).

   Dunivan Q, et al. — Leukocyte-poor platelet-rich plasma reduces retear risk after arthroscopic rotator cuff repair: a meta-analysis with mechanistic and economic evaluation.. J Shoulder Elbow Surg, 2026. DOI: 10.1016/j.jse.2026.02.018.

7. FDA states verbatim that stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products 'have [not] been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.